{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Precursor+Cell+Lymphoblastic+Leukemia-Lymphoma&page=59",
    "query": {
      "condition": "Precursor Cell Lymphoblastic Leukemia-Lymphoma",
      "page": 59
    },
    "page_size": 10
  },
  "pagination": {
    "page": 59,
    "page_size": 10,
    "total_count": 1728,
    "total_pages": 173,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Precursor+Cell+Lymphoblastic+Leukemia-Lymphoma&page=60&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Precursor+Cell+Lymphoblastic+Leukemia-Lymphoma&page=58&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T06:30:11.899Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00349596",
      "title": "A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Lymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "Decitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 40,
      "start_date": "2006-07",
      "completion_date": "2014-10",
      "has_results": false,
      "last_update_posted_date": "2014-10-15",
      "last_synced_at": "2026-11-19T06:30:11.899Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00349596"
    },
    {
      "nct_id": "NCT01076270",
      "title": "Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Accelerated Phase Chronic Myelogenous Leukemia",
        "Adult Acute Lymphoblastic Leukemia in Remission",
        "Adult Acute Myeloid Leukemia in Remission",
        "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities",
        "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)",
        "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)",
        "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)",
        "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)",
        "Atypical Chronic Myeloid Leukemia, BCR-ABL Negative",
        "Blastic Phase Chronic Myelogenous Leukemia",
        "Chronic Phase Chronic Myelogenous Leukemia",
        "de Novo Myelodysplastic Syndromes",
        "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue",
        "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable",
        "Nodal Marginal Zone B-cell Lymphoma",
        "Noncontiguous Stage II Adult Burkitt Lymphoma",
        "Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma",
        "Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma",
        "Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma",
        "Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma",
        "Noncontiguous Stage II Adult Lymphoblastic Lymphoma",
        "Noncontiguous Stage II Grade 1 Follicular Lymphoma",
        "Noncontiguous Stage II Grade 2 Follicular Lymphoma",
        "Noncontiguous Stage II Grade 3 Follicular Lymphoma",
        "Noncontiguous Stage II Mantle Cell Lymphoma",
        "Noncontiguous Stage II Marginal Zone Lymphoma",
        "Noncontiguous Stage II Small Lymphocytic Lymphoma",
        "Previously Treated Myelodysplastic Syndromes",
        "Recurrent Adult Acute Lymphoblastic Leukemia",
        "Recurrent Adult Acute Myeloid Leukemia",
        "Recurrent Adult Burkitt Lymphoma",
        "Recurrent Adult Diffuse Large Cell Lymphoma",
        "Recurrent Adult Diffuse Mixed Cell Lymphoma",
        "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma",
        "Recurrent Adult Hodgkin Lymphoma",
        "Recurrent Adult Immunoblastic Large Cell Lymphoma",
        "Recurrent Adult Lymphoblastic Lymphoma",
        "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma",
        "Recurrent Grade 1 Follicular Lymphoma",
        "Recurrent Grade 2 Follicular Lymphoma",
        "Recurrent Grade 3 Follicular Lymphoma",
        "Recurrent Mantle Cell Lymphoma",
        "Recurrent Marginal Zone Lymphoma",
        "Recurrent Mycosis Fungoides/Sezary Syndrome",
        "Recurrent Small Lymphocytic Lymphoma",
        "Refractory Chronic Lymphocytic Leukemia",
        "Refractory Hairy Cell Leukemia",
        "Refractory Multiple Myeloma",
        "Relapsing Chronic Myelogenous Leukemia",
        "Secondary Acute Myeloid Leukemia",
        "Secondary Myelodysplastic Syndromes",
        "Splenic Marginal Zone Lymphoma",
        "Stage I Multiple Myeloma",
        "Stage II Multiple Myeloma",
        "Stage III Adult Burkitt Lymphoma",
        "Stage III Adult Diffuse Large Cell Lymphoma",
        "Stage III Adult Diffuse Mixed Cell Lymphoma",
        "Stage III Adult Diffuse Small Cleaved Cell Lymphoma",
        "Stage III Adult Hodgkin Lymphoma",
        "Stage III Adult Immunoblastic Large Cell Lymphoma",
        "Stage III Adult Lymphoblastic Lymphoma",
        "Stage III Chronic Lymphocytic Leukemia",
        "Stage III Grade 1 Follicular Lymphoma",
        "Stage III Grade 2 Follicular Lymphoma",
        "Stage III Grade 3 Follicular Lymphoma",
        "Stage III Mantle Cell Lymphoma",
        "Stage III Marginal Zone Lymphoma",
        "Stage III Multiple Myeloma",
        "Stage III Small Lymphocytic Lymphoma",
        "Stage IV Adult Burkitt Lymphoma",
        "Stage IV Adult Diffuse Large Cell Lymphoma",
        "Stage IV Adult Diffuse Mixed Cell Lymphoma",
        "Stage IV Adult Diffuse Small Cleaved Cell Lymphoma",
        "Stage IV Adult Hodgkin Lymphoma",
        "Stage IV Adult Immunoblastic Large Cell Lymphoma",
        "Stage IV Adult Lymphoblastic Lymphoma",
        "Stage IV Chronic Lymphocytic Leukemia",
        "Stage IV Grade 1 Follicular Lymphoma",
        "Stage IV Grade 2 Follicular Lymphoma",
        "Stage IV Grade 3 Follicular Lymphoma",
        "Stage IV Mantle Cell Lymphoma",
        "Stage IV Marginal Zone Lymphoma",
        "Stage IV Small Lymphocytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "plerixafor",
          "type": "DRUG"
        },
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "allogeneic hematopoietic stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 1,
      "start_date": "2010-06",
      "completion_date": "2011-02",
      "has_results": true,
      "last_update_posted_date": "2017-06-28",
      "last_synced_at": "2026-11-19T06:30:11.899Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01076270"
    },
    {
      "nct_id": "NCT00593554",
      "title": "Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Acute Lymphoblastic Leukemia",
        "Myelodysplasia",
        "Chronic Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Total Body Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Thiotepa",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Rabbit ATG",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Palifermin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Sherif S. Farag",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 9,
      "start_date": "2007-08-07",
      "completion_date": "2017-07-28",
      "has_results": true,
      "last_update_posted_date": "2018-04-10",
      "last_synced_at": "2026-11-19T06:30:11.899Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00593554"
    },
    {
      "nct_id": "NCT00290641",
      "title": "Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Chronic Myeloproliferative Disorders",
        "Leukemia",
        "Lymphoma",
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "graft-versus-tumor induction therapy",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "mycophenolate mofetil",
          "type": "DRUG"
        },
        {
          "name": "umbilical cord blood transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "Up to 45 Years"
      },
      "enrollment_count": 68,
      "start_date": "2001-04",
      "completion_date": "2006-01",
      "has_results": false,
      "last_update_posted_date": "2017-11-29",
      "last_synced_at": "2026-11-19T06:30:11.899Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00290641"
    },
    {
      "nct_id": "NCT01137825",
      "title": "Registry of Older Patients With Cancer",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Chronic Myeloproliferative Disorders",
        "Cognitive/Functional Effects",
        "Leukemia",
        "Lymphoma",
        "Lymphoproliferative Disorder",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Neoplasms",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 3000,
      "start_date": "2009-09",
      "completion_date": "2030-12",
      "has_results": false,
      "last_update_posted_date": "2026-06-29",
      "last_synced_at": "2026-11-19T06:30:11.899Z",
      "location_count": 7,
      "location_summary": "Boone, North Carolina • Chapel Hill, North Carolina • Greenville, North Carolina + 4 more",
      "locations": [
        {
          "city": "Boone",
          "state": "North Carolina"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Greenville",
          "state": "North Carolina"
        },
        {
          "city": "Hendersonville",
          "state": "North Carolina"
        },
        {
          "city": "Morehead City",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01137825"
    },
    {
      "nct_id": "NCT03241940",
      "title": "Study of CD19/CD22 Chimeric Antigen Receptor T Cells in Children & Young Adults w/ Recurrent or Refractory B Cell Malignancies",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "B Acute Lymphoblastic Leukemia",
        "CD19 Positive",
        "Minimal Residual Disease",
        "Philadelphia Chromosome Positive",
        "Recurrent Adult Acute Lymphoblastic Leukemia",
        "Recurrent Childhood Acute Lymphoblastic Leukemia",
        "Refractory Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "Chimeric Antigen Receptor T-Cell Therapy",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "1 Year to 30 Years"
      },
      "enrollment_count": 33,
      "start_date": "2017-10-20",
      "completion_date": "2035-08-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-30",
      "last_synced_at": "2026-11-19T06:30:11.899Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03241940"
    },
    {
      "nct_id": "NCT03595917",
      "title": "ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "B-cell Acute Lymphoblastic Leukemia",
        "Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis",
        "Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL"
      ],
      "interventions": [
        {
          "name": "ABL001",
          "type": "DRUG"
        },
        {
          "name": "Dasatinib",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Blinatumomab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Marlise Luskin, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2018-07-24",
      "completion_date": "2027-11-01",
      "has_results": false,
      "last_update_posted_date": "2025-11-04",
      "last_synced_at": "2026-11-19T06:30:11.899Z",
      "location_count": 4,
      "location_summary": "Chicago, Illinois • Boston, Massachusetts • Buffalo, New York",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03595917"
    },
    {
      "nct_id": "NCT06173518",
      "title": "A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia",
        "Relapsed or Refractory B Cell Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "AUTO1",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Autolus Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "0 Years to 18 Years"
      },
      "enrollment_count": 30,
      "start_date": "2023-11-16",
      "completion_date": "2027-11",
      "has_results": false,
      "last_update_posted_date": "2026-11-13",
      "last_synced_at": "2026-11-19T06:30:11.899Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • Palo Alto, California • Aurora, Colorado + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06173518"
    },
    {
      "nct_id": "NCT00672152",
      "title": "A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Transplantation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myelogenous Leukemia (AML)",
        "Chronic Myelogenous Leukemia (CML)",
        "Acute Lymphoblastic Leukemia (ALL)",
        "Myelodysplastic Syndrome (MDS)",
        "B Cell Malignancies"
      ],
      "interventions": [
        {
          "name": "WT1 derived peptides",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Michael Morse, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2007-06",
      "completion_date": "2013-10",
      "has_results": false,
      "last_update_posted_date": "2013-12-10",
      "last_synced_at": "2026-11-19T06:30:11.899Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00672152"
    },
    {
      "nct_id": "NCT02065154",
      "title": "Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia",
        "Lymphoma",
        "Myelodysplastic Syndrome",
        "Myelofibrosis",
        "Severe Aplastic Anemia",
        "Allogeneic Transplant"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "19 Years to 65 Years"
      },
      "enrollment_count": 39,
      "start_date": "2013-08-27",
      "completion_date": "2022-04",
      "has_results": true,
      "last_update_posted_date": "2022-09-30",
      "last_synced_at": "2026-11-19T06:30:11.899Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02065154"
    }
  ]
}